Scarica l'app Stockscreener
58.75
3.04%
-1.84
Dopo l'orario di chiusura:
58.75
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$60.59
Aprire:
$60.445
Volume 24 ore:
3.32M
Relative Volume:
1.07
Capitalizzazione di mercato:
$26.16B
Reddito:
$2.44B
Utile/perdita netta:
$1.36B
Rapporto P/E:
30.77
EPS:
1.9093
Flusso di cassa netto:
$574.14M
1 W Prestazione:
-8.03%
1M Prestazione:
+1.35%
6M Prestazione:
+27.80%
1 anno Prestazione:
+62.38%
Intervallo 1D:
$58.64
$60.71
Intervallo di 1 settimana:
$58.63
$64.38
Portata 52W:
$34.63
$64.38
Royalty Pharma Plc Stock (RPRX) Company Profile
Nome
Royalty Pharma Plc
Settore
Industria
Telefono
(212) 883-0200
Indirizzo
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
58.75 | 26.98B | 2.44B | 1.36B | 574.14M | 1.9093 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-30 | Aggiornamento | UBS | Neutral → Buy |
| 2025-09-30 | Iniziato | Goldman | Buy |
| 2025-05-16 | Iniziato | Morgan Stanley | Overweight |
| 2024-06-03 | Downgrade | UBS | Buy → Neutral |
| 2022-06-14 | Ripresa | UBS | Buy |
| 2022-05-13 | Iniziato | Scotiabank | Sector Outperform |
| 2022-04-27 | Iniziato | Goldman | Buy |
| 2022-04-14 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2021-10-29 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-07-30 | Iniziato | Tigress Financial | Buy |
| 2020-11-09 | Aggiornamento | UBS | Neutral → Buy |
| 2020-07-14 | Iniziato | Evercore ISI | In-line |
| 2020-07-13 | Iniziato | BofA Securities | Buy |
| 2020-07-13 | Iniziato | Citigroup | Neutral |
| 2020-07-13 | Iniziato | Cowen | Outperform |
| 2020-07-13 | Iniziato | Goldman | Neutral |
| 2020-07-13 | Iniziato | JP Morgan | Neutral |
| 2020-07-13 | Iniziato | Morgan Stanley | Equal-Weight |
| 2020-07-13 | Iniziato | SunTrust | Buy |
| 2020-07-13 | Iniziato | UBS | Neutral |
Mostra tutto
Royalty Pharma Plc Borsa (RPRX) Ultime notizie
Royalty Pharma (RPRX): Can Downside Protection Offset Pelacarsen’s Phase 3 Failure? - Yahoo Finance
Squarepoint Ops LLC Decreases Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma to present at Morgan Stanley global healthcare investor conference - Bitget
Royalty Pharma to present at upcoming investor conferences - marketscreener.com
Royalty Pharma to Present at Upcoming Investor Conferences - Moomoo
Royalty Pharma PLC $RPRX Shares Sold by C WorldWide Group Holding A S - MarketBeat
If You Invested $1000 In Royalty Pharma Stock 15 Years Ago, You Would Have This Much Today - Benzinga
TD Cowen raises Royalty Pharma stock price target on unchanged growth outlook - Investing.com Nigeria
Royalty Pharma (NASDAQ:RPRX) Shares Gap DownWhat's Next? - MarketBeat
RPRX Maintained by TD Cowen -- Price Target Raised to $68.00 - GuruFocus
Royalty Pharma (RPRX) PT Raised to $68 at TD Cowen - StreetInsider
TD Cowen Issues Positive Forecast for Royalty Pharma (NASDAQ:RPRX) Stock Price - MarketBeat
Why Is Novartis Stock Falling Today?Novartis (NYSE:NVS), Ionis Pharmaceuticals (NASDAQ:IONS), Royalty - Benzinga
Royalty Pharma PLC (RPRX) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC $RPRX Position Increased by TD Waterhouse Canada Inc. - MarketBeat
Royalty Pharma plc (RPRX) Stock Analysis: Navigating Growth with a 16.5% Revenue Surge - DirectorsTalk Interviews
Royalty Pharma Updates on Novartis' HORIZON Trial Results - Intellectia AI
Royalty Pharma expects modest return despite pelacarsen trial failure - Investing.com
Royalty Pharma Announces Novartis HORIZON Pelacarsen Trial Results and Updates Return Outlook on Ionis Funding Agreement - Quiver Quantitative
Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen - pmg-ky3.com
Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen - GlobeNewswire Inc.
Royalty Pharma Slides as Higher-Rate Jitters Seem to Outweigh Recent Strong Results - Quiver Quantitative
Trading the Move, Not the Narrative: (RPRX) Edition - Stock Traders Daily
Teva posts mid-stage trial win for celiac disease therapy developed with Royalty Pharma - Seeking Alpha
Royalty Pharma stock hits all-time high at 62.48 USD By Investing.com - Investing.com Australia
Public Employees Retirement System of Ohio Makes New $7.84 Million Investment in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma (RPRX) Bets $100M On A Blood Disorder Breakthrough - Yahoo Finance
Royalty Pharma (NASDAQ:RPRX) Sets New 52-Week HighWhat's Next? - MarketBeat
Royalty Pharma stock hits all-time high at 62.48 USD - Investing.com
Royalty Pharma Plc (RPRX) Stock Analysis: Unpacking A 6.41% Potential Upside - DirectorsTalk Interviews
Headlands Technologies LLC Invests $5.09 Million in Royalty Pharma PLC $RPRX - MarketBeat
Wall Street Zen Downgrades Royalty Pharma (NASDAQ:RPRX) to Buy - MarketBeat
Royalty Pharma: Strong Execution, Higher Guidance, And Room For A Re-Rating (NASDAQ:RPRX) - Seeking Alpha
Royalty Pharma (NASDAQ:RPRX) Hits New 1-Year HighHere's What Happened - MarketBeat
Royalty Pharma plc (RPRX) Stock Analysis: Strong Buy Ratings and Promising Growth in the Biotech Sector - DirectorsTalk Interviews
Is Royalty Pharma (RPRX) Undervalued On Its $100 Million Zealand Pharma Royalty Deal? - Sahm
Wall Street Zen Upgrades Royalty Pharma (NASDAQ:RPRX) to "Strong-Buy" - MarketBeat
If You Invested $1000 In Royalty Pharma Stock 10 Years Ago, You Would Have This Much Today - Benzinga
RPHC5824520 Bond Profile — Key Metrics - TradingView
30,000 Shares in Royalty Pharma PLC $RPRX Purchased by Monetta Financial Services Inc. - MarketBeat
Royalty Pharma EVP Christopher Hite Sells 100,000 Shares and Donates 16,800 Shares to Charity - Kalkine Media
Royalty Pharma (NASDAQ:RPRX) EVP Christopher Hite Sells 100,000 Shares of Stock - MarketBeat
Royalty Pharma (NASDAQ: RPRX) exec sells 100K shares, donates stock - Stock Titan
Royalty Pharma (NASDAQ:RPRX) Sets New 1-Year HighHere's What Happened - MarketBeat
Royalty Pharma stock hits all-time high at 60.44 USD - Investing.com
Royalty Pharma stock hits all-time high at 60.44 USD By Investing.com - Investing.com Nigeria
Tranche Update on Royalty Pharma plc's Equity Buyback Plan announced on January 10, 2025. - marketscreener.com
Commerzbank Aktiengesellschaft FI Invests $1.20 Million in Royalty Pharma PLC $RPRX - MarketBeat
How Investors Are Reacting To Royalty Pharma (RPRX) Buying Rusfertide Royalties From Zealand Pharma - simplywall.st
Royalty Pharma (NASDAQ: RPRX) holder plans multi-million share sale - Stock Titan
Royalty Pharma EVP & CFO Terrance Coyne sells $645k in shares - Investing.com South Africa
Royalty Pharma Plc Azioni (RPRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.18%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):